# Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

> **NCT05024019** · PHASE2 · UNKNOWN · sponsor: **Eye & ENT Hospital of Fudan University** · enrollment: 95 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nimotuzumab

## Key facts

- **NCT ID:** NCT05024019
- **Lead sponsor:** Eye & ENT Hospital of Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-21
- **Primary completion:** 2025-08-21
- **Final completion:** 2025-08-21
- **Target enrollment:** 95 (ESTIMATED)
- **Last updated:** 2021-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05024019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05024019, "Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05024019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*